| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tulane University Health Sciences Center, New Orleans, LA 70112; King Edward Medical College, Lahore 54000 Pakistan
* To whom correspondence should be addressed. E-mail: vfonseca{at}tulane.edu.
This commentary has no abstract.
This article has been cited by other articles:
![]() |
D. J. Betteridge, R. A. DeFronzo, and R. J. Chilton PROactive: time for a critical appraisal Eur. Heart J., April 2, 2008; 29(8): 969 - 983. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Misbin Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes Diabetes Care, December 1, 2007; 30(12): 3141 - 3144. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |